Searchable abstracts of presentations at key conferences in endocrinology

ea0090pl3 | Novel form of hypophysitis: New kids on the block | ECE2023

Novel form of hypophysitis: New kids on the block

Takahashi Yutaka

Hypophysitis is classified according to the anatomic location of pituitary involvement and the cause (primary or secondary forms). The primary forms are characterized by an idiopathic inflammatory process confined to the pituitary gland, while the secondary forms are triggered by a definite etiology. Recently, as a secondary form of hypophysitis, an immune-mediated paraneoplastic syndrome defined as paraneoplastic autoimmune hypophysitis has been reported. This novel clinical ...

ea0070aep579 | Pituitary and Neuroendocrinology | ECE2020

Once-weekly somapacitan in japanese adults with growth hormone deficiency was well tolerated, with similar efficacy to daily growth hormone: A randomised trial

Otsuka Fumio , Takahashi Yutaka , Tahara Shigeyuki , Ogawa Yoshihisa , Højby Rasmussen Michael , Takano Koji

Somapacitan is a long-acting, reversible albumin-binding growth hormone (GH) derivative. The objective of this trial was to evaluate the safety, efficacy and treatment satisfaction of onceweekly somapacitan versus daily GH (Norditropin) over 52 weeks in Japanese patients with adult GH deficiency (AGHD). This was a phase 3, multicentre, randomised, open-label, parallel-group, active-controlled trial (NCT03075644). Patients previously treated with GH were randomised 1:3 to daily...

ea0081p415 | Pituitary and Neuroendocrinology | ECE2022

Effects of somapacitan on glucose metabolism in adults with GH deficiency

Johannsson Gudmundur , MK Biller Beverly , Fukuoka Hidenori , Ho Ken , Hojby Rasmussen Michael , Nedjatian Navid , Svaerke Claus , CJ Yuen Kevin , Takahashi Yutaka

Somapacitan is a once-weekly, long-acting growth hormone (GH) derivative approved for the treatment of adult GH deficiency (AGHD). Our objective was to evaluate the effects of somapacitan on glucose metabolism compared with daily GH or placebo in patients with AGHD using data from three previously published phase 3 trials: REAL 1 (NCT02229851), REAL 2 (NCT02382939) and REAL Japan (NCT03075644). REAL 1 was a randomised, placebo-controlled (double-blind) and active-controlled (o...